Following treatment with nilotinib, we identified significant changes in expression of miRNAs that interact with SOD3 (hsa-miR-6794-5p), APP (hsa-miR-302c-3p), presenilin (hsa-miR-1233-5p, hsa-miR-6829-3p), BACE1 (hsa-miR-4531), BDNF (hsa-miR-1-3p), CYCS (hsa-miR-3925-3p, hsa-miR-454-5p, hsa-miR-6797-3p), TCERG1 (hsa-miR-4262), and HDAC (hsa-miR-4634, hsa-miR-6794-5p, hsa-miR-3189-3p, hsa-miR-326), genes associated with pathogenesis in such diseases as AD, PD, and Amyotrophic Lateral Sclerosis (ALS), in addition to HD, as shown in Figure S3. This evidence concerns the gene SOD3 and Huntington disease.